<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Dec. 31, 2019 (HealthDay News) — A novel cathepsin K inhibitor, MIV-711, is no more effective than placebo for reducing pain in patients with symptomatic, radiographic knee osteoarthritis, according to a study published online Dec. 31 in the Annals of Internal Medicine<\/i>.<\/p>\n
Philip G. Conaghan, M.B.B.S., Ph.D., from the University of Leeds in the United Kingdom, and colleagues examined the efficacy, safety, and tolerability of MIV-711 in participants with symptomatic, radiographic knee osteoarthritis in a 26-week randomized, double-blind, placebo-controlled phase 2a trial with a 26-week open-label safety expansion. Patients received either MIV-711 100 mg daily (82 patients), 200 mg daily (81 patients), or matched placebo (77 patients). During the extension substudy, 46 patients who initially received 200 mg\/day and four who received placebo received 200 mg of MIV-711 daily.<\/p>\n
The researchers observed no significant changes in numerical rating scale pain scores with MIV-711 (placebo, \u22121.4; MIV-711 100 mg\/day, \u22121.7; MIV-711 200 mg\/day, \u22121.5). Significant reductions in medial femoral bone area progression and medial femoral cartilage thinning were seen for MIV-711 100 and 200 mg\/day versus placebo; there were also substantial reductions noted in bone and cartilage biomarker levels. In six participants, there were nine serious adverse events; however, none were thought to be related to treatment.<\/p>\n
“Further evaluation of MIV-711 in longer and larger trials to confirm the structural benefits observed here and whether these translate to more tangible benefits on symptoms is warranted,” the authors write.<\/p>\n
Several authors disclosed ties to pharmaceutical companies, including Medivir, which manufactures MIV-711 and partially funded the study.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n